Clopidogrel Acino यूरोपीय संघ - पुर्तगाली - EMA (European Medicines Agency)

clopidogrel acino

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - agentes antitrombóticos - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

NORFLOXACINO ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

norfloxacino

pharmascience indÚstria farmacÊutica ltda - norfloxacino - antibioticos sistemicos simples

NORFLOXACINO ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

norfloxacino

sandoz do brasil indÚstria farmacÊutica ltda - norfloxacino - antibioticos sistemicos simples

NORFLOXACINO ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

norfloxacino

uniÃo quÍmica farmacÊutica nacional s/a - norfloxacino - antibioticos sistemicos simples

norfloxacino ब्राज़ील - पुर्तगाली - ANVISA (Agência Nacional de Vigilância Sanitária)

norfloxacino

brainfarma indÚstria quÍmica e farmacÊutica s.a - norfloxacino - antibioticos sistemicos simples